Knowles Julius's Form 4 filing
Keros Therapeutics, Inc. (KROS) · filed Oct 18, 2021
- Accession no.
- 0001209191-21-060784
- Filed
- Oct 18, 2021
- Trade date
- Oct 14-18, 2021
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 12 non-derivative transactions. Open-market sales total $1.02M. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Knowles JuliusCIK 0001808365 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Oct 14, 2021 | Common Stock | SSaleDisposed | −2,653 | $40.13F2 | −$106,464.89 | 446,608 | Indirect | |
| Oct 14, 2021 | Common Stock | SSaleDisposed | −1,730 | $40.13F2 | −$69,424.9 | 301,228 | Indirect | |
| Oct 15, 2021 | Common Stock | SSaleDisposed | −3,031 | $38.95F5 | −$118,057.45 | 443,577 | Indirect | |
| Oct 15, 2021 | Common Stock | SSaleDisposed | −1,977 | $38.95F5 | −$77,004.15 | 299,251 | Indirect | |
| Oct 15, 2021 | Common Stock | SSaleDisposed | −1,839 | $39.44F6 | −$72,530.16 | 441,738 | Indirect | |
| Oct 15, 2021 | Common Stock | SSaleDisposed | −1,199 | $39.44F6 | −$47,288.56 | 298,052 | Indirect | |
| Oct 15, 2021 | Common Stock | SSaleDisposed | −92 | $40.60 | −$3,735.2 | 441,646 | Indirect | |
| Oct 15, 2021 | Common Stock | SSaleDisposed | −60 | $40.60 | −$2,436 | 297,992 | Indirect | |
| Oct 18, 2021 | Common Stock | SSaleDisposed | −8,252 | $37.69F7 | −$311,017.88 | 433,394 | Indirect | |
| Oct 18, 2021 | Common Stock | SSaleDisposed | −5,382 | $37.69F7 | −$202,847.58 | 292,610 | Indirect | |
| Oct 18, 2021 | Common Stock | SSaleDisposed | −92 | $38.46 | −$3,538.32 | 433,302 | Indirect | |
| Oct 18, 2021 | Common Stock | SSaleDisposed | −60 | $38.46 | −$2,307.6 | 292,550 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.00 to $40.71 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (5), (6) and (7).
Referenced by the price of 2 transactions in Table I.
- F5
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.29 to $39.28 inclusive.
Referenced by the price of 2 transactions in Table I.
- F6
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.29 to $40.11 inclusive.
Referenced by the price of 2 transactions in Table I.
- F7
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.36 to $38.30 inclusive.
Referenced by the price of 2 transactions in Table I.